ConductScience.org, home

Comparison · NCT00906347-sae

Misoprostol Augmentation vs Oxytocin Augmentation: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Misoprostol Augmentation vs Oxytocin Augmentation: serious adverse events. Trial comparisons, record NCT00906347-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00906347-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.005680.0010.0315wilson
Risk in group 20.01150.003160.0409wilson
Risk difference, group 1 minus group 2-0.00581-0.03560.0213newcombe hybrid score
Risk ratio, group 1 over group 20.4940.04525.4log
Odds ratio, group 1 over group 20.4910.04425.47log
Number needed to treat, for one fewer participant with a serious adverse event on Misoprostol Augmentation than on Oxytocin Augmentation172from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Misoprostol AugmentationWomen with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.~Misoprostol : 75 micrograms orally every 4 hours for up to 2 doses.1176EG000
Group 2Oxytocin Augmentation
Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.~Oxytocin : Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
2174EG001

Harm

What it counts
Total, serious adverse events
Time frame
During study period

Source ClinicalTrials.gov

Trial

Title
A Trial of Oral Misoprostol for Labor Augmentation
NCT number
NCT00906347
Phases
PHASE4
Conditions
Labor Augmentation
Interventions
Misoprostol, Oxytocin
Lead sponsor
University of Texas Southwestern Medical Center
Results first posted
2012-11-07

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00906347-sae